-- Provides Sales and Earnings Projections for 2009 -- LAKE FOREST,
Ill., Feb. 17 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE:HSP), a
leading global specialty pharmaceutical and medication delivery
company, today reported results for the fourth quarter and full
year ended Dec. 31, 2008. For the fourth quarter of 2008, net sales
were $914 million, and adjusted* diluted earnings per share were
$0.78. For the full year of 2008, net sales were $3.6 billion, and
adjusted* diluted earnings per share were $2.53. (Adjusted*
measures exclude certain specified items as described later in this
press release and the attached schedules.) "Hospira delivered
another positive year of performance in 2008, generating solid
revenue and strong profit growth, further advancing key areas of
our business and successfully completing the integration of the
Mayne Pharma acquisition," said Christopher B. Begley, chairman and
chief executive officer. "Looking forward, as a diversified
healthcare company primarily serving the acute-care market, Hospira
is well positioned in 2009. Hospira's underlying businesses remain
solid, and we expect another year of growth guided by our focus on
execution and operational optimization." Fourth-Quarter 2008
Results The following table highlights selected financial results
for the fourth quarter of 2008 compared to the same period in 2007:
In $ millions, GAAP Adjusted* except per Three Months Ended Three
Months Ended share amounts Dec. 31, Dec. 31, ---------------- %
---------------- % 2008 2007 Change 2008 2007 Change ------ ------
------ ------ ------ ------ Net Sales $913.7 $946.1 (3.4)% n/a n/a
n/a Gross Profit $348.6 $338.6 3.0 % $376.4 $363.7 3.5 % Income
from Operations $155.7 $114.0 36.6 % $188.2 $153.6 22.5 % Diluted
EPS $0.65 $0.47 38.3 % $0.78 $0.63 23.8 % Statistics (as a % of Net
Sales) -------------------------------- Gross Profit 38.2 % 35.8 %
41.2 % 38.4 % Operating Income 17.0 % 12.0 % 20.6 % 16.2 % Results
under U.S. Generally Accepted Accounting Principles (GAAP) include
items as detailed in the schedules attached to this press release.
Net sales decreased 3.4 percent to $914 million in the fourth
quarter of 2008, compared to $946 million in the fourth quarter of
2007. The decline was primarily driven by three factors:
unfavorable foreign currency translation; unusually high U.S.
wholesaler purchasing patterns for Specialty Injectable
Pharmaceuticals in the fourth quarter of 2007; and decreased demand
in Other Pharma from some contract manufacturing customers.
Medication Management Systems (MMS) reported solid sales growth
based on continued demand for its newest general infusion system,
Symbiq(R). Adjusted* operating income increased 22.5 percent to
$188 million in the fourth quarter of 2008, compared to $154
million in the fourth quarter of 2007. Contributing to the increase
was favorable volume/mix, improved manufacturing efficiency and the
impact of Selling, General & Administrative (SG&A)
cost-containment measures. Full-Year 2008 Results The following
table highlights selected financial results for the full year 2008
compared to the same period in 2007: In $ millions, GAAP Adjusted*
except per Year Ended Year Ended share amounts Dec. 31, Dec. 31,
---------------- % ---------------- % 2008 2007 Change 2008 2007
Change ------ ------ ------ ------ ------ ------ Net Sales $3,629.5
$3,436.2 5.6 % n/a n/a n/a Gross Profit $1,322.0 $1,173.9 12.6 %
$1,426.5 $1,325.1 7.7 % Income from Operations $517.8 $302.6 71.1 %
$647.1 $579.6 11.6 % Diluted EPS $1.99 $0.85 134.1 % $2.53 $2.19
15.5 % Statistics (as a % of Net Sales)
-------------------------------- Gross Profit 36.4 % 34.2 % 39.3 %
38.6 % Operating Income 14.3 % 8.8 % 17.8 % 16.9 % Net sales
increased 5.6 percent to $3.6 billion for the year ended Dec. 31,
2008, compared to $3.4 billion for the prior year. The increase was
primarily a result of the impact of new group purchasing
organization (GPO) awards; strong demand for the company's MMS
product lines; and favorable foreign currency translation.
Adjusted* operating income increased 11.6 percent to $647 million
for the full year of 2008, compared to $580 million for the full
year of 2007. The increase is primarily a result of favorable
volume/mix, improved manufacturing efficiencies and the impact of
foreign exchange. Cash Flow Cash flow from operations for the
full-year 2008 was $584 million, an increase compared to the $551
million generated in 2007. Capital expenditures were $164 million
for the full year, compared to $211 million in 2007. The decline is
partly due to lower spending in 2008 than in 2007 related to the
company's facilities optimization initiatives, as well as to
capital-spending controls the company effected in the second half
of 2008. 2009 Projections Hospira expects net sales growth for
full-year 2009 to be approximately 4 to 6 percent on a
constant-currency basis. Including the impact of foreign exchange,
the company expects net sales to be relatively flat. Adjusted*
diluted earnings per share for 2009 are expected to be in the range
of $2.62 to $2.72. The reconciliation between the projected 2009
adjusted* diluted earnings per share and GAAP diluted earnings per
share follows: Diluted earnings per share -- adjusted* $2.62 -
$2.72 -------------- Estimated charges related to planned
facilities optimization initiatives (mid-point of an estimated
range of $0.10 to $0.12 per diluted share for 2009) ($0.11)
Estimated $53 million for the amortization of intangibles related
to the Mayne Pharma acquisition ($0.23) -------------- Diluted
earnings per share -- GAAP $2.28 - $2.38 ============== The company
projects that cash flow from operations in 2009 will be in the $565
million to $615 million range. Depreciation and amortization is
expected to be between $210 million and $220 million. Capital
expenditures are projected to be between $155 million and $175
million. "Our 2009 guidance aligns with our core strategies to
improve margins and cash flow and invest for growth," said Begley.
"We have a robust global generic drug pipeline and attractive
growth opportunities in generic injectables. With our expanded GPO
contracts, we expect to attract additional customers to our broad
portfolio of products. We also expect continued momentum with MMS
as we advance our technologically enhanced offerings. Through our
streamlined, focused management and optimization initiatives, we
are well positioned to advance our growth opportunities and drive
sustainable long-term growth." *Use of Non-GAAP Financial Measures
Non-GAAP financial measures used in this press release are
reconciled to the most comparable measures calculated in accordance
with GAAP in the schedules attached to this release. For more
information regarding these non-GAAP financial measures, please see
Hospira's Current Report on Form 8-K filed with the Securities and
Exchange Commission on the date of this press release. Webcast
Hospira will hold a conference call for investors and media at 8
a.m. Central time on Tuesday, Feb. 17, 2009. A live webcast of the
conference call will be available at
http://www.hospirainvestor.com/. Listeners should log on
approximately 10 minutes in advance to ensure proper computer setup
for receiving the webcast. A replay will be available on the
Hospira Web site for 30 days following the call. About Hospira
Hospira, Inc. is a global specialty pharmaceutical and medication
delivery company dedicated to Advancing Wellness(TM). As the world
leader in specialty generic injectable pharmaceuticals, Hospira
offers one of the broadest portfolios of generic acute-care and
oncology injectables, as well as integrated infusion therapy and
medication management solutions. Through its products, Hospira
helps improve the safety, cost and productivity of patient care.
The company is headquartered in Lake Forest, Ill., and has
approximately 14,000 employees. Learn more at
http://www.hospira.com/. Private Securities Litigation Reform Act
of 1995 -- A Caution Concerning Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including projections of certain measures of Hospira's results of
operations, projections of certain charges and expenses, and other
statements regarding Hospira's goals and strategy. Hospira cautions
that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those indicated in the forward-looking statements. Economic,
competitive, governmental, technological and other factors that may
affect Hospira's operations and may cause actual results to be
materially different from expectations include the risks,
uncertainties and factors discussed under the headings "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" in Hospira's latest Annual
Report on Form 10-K and subsequent Forms 10-Q, filed with the
Securities and Exchange Commission, which is incorporated by
reference. Hospira undertakes no obligation to release publicly any
revisions to forward-looking statements as the result of subsequent
events or developments. Hospira, Inc. Condensed Consolidated
Statements of Income (Unaudited) (dollars and shares in millions,
except for per share amounts) Three Months Ended Years Ended
December 31, December 31, --------------- % ------------------ %
2008 2007 Change 2008 2007 Change ------ ------ ------- --------
-------- ------- Net sales $913.7 $946.1 (3.4)% $3,629.5 $3,436.2
5.6 % Cost of products sold 565.1 607.5 (7.0)% 2,307.5 2,262.3 2.0
% ------ ------ -------- -------- Gross Profit 348.6 338.6 3.0 %
1,322.0 1,173.9 12.6 % Research and development 53.5 53.7 (0.4)%
213.6 201.2 6.2 % Acquired in-process research and development -
3.2 (100.0)% 0.5 88.0 (99.4)% Selling, general and administrative
139.4 167.7 (16.9)% 590.1 582.1 1.4 % ------ ------ --------
-------- Income From Operations 155.7 114.0 36.6 % 517.8 302.6 71.1
% Interest expense 29.0 32.0 (9.4)% 116.2 134.5 (13.6)% Other
expense (income), net 0.6 (7.7)(107.8)% (5.9) (19.7) (70.1)% ------
------ -------- -------- Income Before Income Taxes 126.1 89.7 40.6
% 407.5 187.8 117.0 % Income tax expense 21.5 13.6 58.1 % 86.6 51.0
69.8 % ------ ------ -------- -------- Net Income $104.6 $76.1 37.5
% $320.9 $136.8 134.6 % ====== ====== ======== ======== Earnings
Per Common Share: Basic $0.66 $0.48 37.5 % $2.02 $0.87 132.2 %
====== ====== ======== ======== Diluted $0.65 $0.47 38.3 % $1.99
$0.85 134.1 % ====== ====== ======== ======== Weighted Average
Common Shares Outstanding: Basic 159.5 157.8 1.1 % 159.2 156.9 1.5
% ====== ====== ======== ======== Diluted 160.9 160.3 0.4 % 161.3
160.2 0.7 % ====== ====== ======== ======== Hospira, Inc.
Reconciliation of Condensed Consolidated Statements of Income
(Unaudited) (dollars and shares in millions, except per share
amounts) Three Months Ended December 31,
------------------------------------------------------- 2008 2007
-------------------------- -------------------------- GAAP
Adjustments Adjusted GAAP Adjustments Adjusted ------ ------ ------
------ ------ ------ Net sales $913.7 $ - $913.7 $946.1 $ - $946.1
Cost of products sold 565.1 (27.8)A 537.3 607.5 (25.1)E 582.4
------ ------ ------ ------ ------ ------ Gross Profit 348.6 27.8
376.4 338.6 25.1 363.7 Research and development 53.5 (0.5)B 53.0
53.7 (0.3)C 53.4 Acquired in-process research and development - - -
3.2 (3.2)G - Selling, general and administrative 139.4 (4.2)C 135.2
167.7 (11.0)C 156.7 ------ ------ ------ ------ ------ ------
Income From Operations 155.7 32.5 188.2 114.0 39.6 153.6 Interest
expense 29.0 - 29.0 32.0 1.4 F 33.4 Other expense (income), net 0.6
- 0.6 (7.7) - (7.7) ------ ------ ------ ------ ------ ------
Income Before Income Taxes 126.1 32.5 158.6 89.7 38.2 127.9 Income
tax expense 21.5 10.8 D 32.3 13.6 14.0 D 27.6 ------ ------ ------
------ ------ ------ Net Income $104.6 $21.7 $126.3 $76.1 $24.2
$100.3 ====== ====== ====== ====== ====== ====== Earnings Per
Common Share: Basic $0.66 $0.13 $0.79 $0.48 $0.16 $0.64 ======
====== ====== ====== ====== ====== Diluted $0.65 $0.13 $0.78 $0.47
$0.16 $0.63 ====== ====== ====== ====== ====== ====== Weighted
Average Common Shares Outstanding: Basic 159.5 159.5 159.5 157.8
157.8 157.8 ====== ====== ====== ====== ====== ====== Diluted 160.9
160.9 160.9 160.3 160.3 160.3 ====== ====== ====== ====== ======
====== Statistics (as a % of Net Sales, except for income tax rate)
----------------- Gross Profit 38.2% 41.2% 35.8% 38.4% R&D 5.9%
5.8% 5.7% 5.6% SG&A 15.3% 14.8% 17.7% 16.6% Income From
Operations 17.0% 20.6% 12.0% 16.2% Income Before Income Taxes 13.8%
17.4% 9.5% 13.5% Net Income 11.4% 13.8% 8.0% 10.6% Income Tax Rate
17.1% 20.4% 15.2% 21.5% % Change vs. Prior Year
----------------------- GAAP Adjusted ------- -------- Net sales
(3.4)% (3.4)% Cost of products sold (7.0)% (7.7)% Gross Profit 3.0
% 3.5 % Research and development (0.4)% (0.7)% Acquired in-process
research and development (100.0)% nm Selling, general and
administrative (16.9)% (13.7)% Income From Operations 36.6 % 22.5 %
Interest expense (9.4)% (13.2)% Other expense (income), net
(107.8)% (107.8)% Income Before Income Taxes 40.6 % 24.0 % Income
tax expense 58.1 % 17.0 % Net Income 37.5 % 25.9 % Earnings Per
Common Share: Basic 37.5 % 23.4 % Diluted 38.3 % 23.8 % Weighted
Average Common Shares Outstanding: Basic 1.1 % 1.1 % Diluted 0.4 %
0.4 % A -- Includes intangible assets amortization of $16.0 related
to the Mayne Pharma acquisition; charges of $9.0 related to the
planned closures of the Ashland, OH; Montreal, Canada; North
Chicago, IL; and Morgan Hill, CA facilities as part of Hospira's
facilities optimization initiatives; and Mayne Pharma integration
and other acquisition- related charges of $2.8. B -- Facilities
optimization initiatives. C -- Mayne Pharma integration and other
acquisition-related charges. D -- Reflects the tax effect of the
above adjustments. E -- Includes intangible assets amortization of
$12.6 related to the Mayne Pharma acquisition; charges of $4.1
related to the planned closures of the Donegal, Ireland; Ashland,
OH; Montreal, Canada; and North Chicago, IL facilities as part of
Hospira's facilities optimization initiatives; Mayne Pharma
integration charges of $0.9; and intangible asset impairment of
$7.5 related to a non-strategic device product. F -- Other
acquisition-related (charge) refund: refund of bridge loan fees
incurred as a result of the Mayne Pharma acquisition expensed upon
refinancing of loan during the first quarter of 2007. G -- Acquired
in-process research and development. nm = Percent change is not
meaningful. Hospira, Inc. Reconciliation of Condensed Consolidated
Statements of Income (Unaudited) (dollars and shares in millions,
except per share amounts) Years Ended December 31,
--------------------------------------------------------- 2008 2007
---------------------------- --------------------------- GAAP
Adjustments Adjusted GAAP Adjustments Adjusted -------- -----
------- ------- ------ ------- Net sales $3,629.5 $ - $3,629.5
$3,436.2 $ - $3,436.2 Cost of products sold 2,307.5 (104.5)A
2,203.0 2,262.3 (151.2)F 2,111.1 -------- ----- ------- -------
------ ------- Gross Profit 1,322.0 104.5 1,426.5 1,173.9 151.2
1,325.1 Research and development 213.6 (3.3)B 210.3 201.2 (1.6)D
199.6 Acquired in-process research and development 0.5 (0.5)C -
88.0 (88.0)C - Selling, general and administrative 590.1 (21.0)D
569.1 582.1 (36.2)D 545.9 -------- ----- ------- ------- ------
------- Income From Operations 517.8 129.3 647.1 302.6 277.0 579.6
Interest expense 116.2 - 116.2 134.5 (0.8)G 133.7 Other expense
(income), net (5.9) - (5.9) (19.7) (5.7)H (25.4) -------- -----
------- ------- ------ ------- Income Before Income Taxes 407.5
129.3 536.8 187.8 283.5 471.3 Income tax expense 86.6 42.1 E 128.7
51.0 69.3 E 120.3 -------- ----- ------- ------- ------ ------- Net
Income $320.9 $87.2 $408.1 $136.8 $214.2 $351.0 ======== =====
======= ======= ====== ======= Earnings Per Common Share: Basic
$2.02 $0.54 $2.56 $0.87 $1.37 $2.24 ======== ===== ======= =======
====== ======= Diluted $1.99 $0.54 $2.53 $0.85 $1.34 $2.19 ========
===== ======= ======= ====== ======= Weighted Average Common Shares
Outstanding: Basic 159.2 159.2 159.2 156.9 156.9 156.9 ========
===== ======= ======= ====== ======= Diluted 161.3 161.3 161.3
160.2 160.2 160.2 ======== ===== ======= ======= ====== =======
Statistics (as a % of Net Sales, except for income tax rate)
----------------- Gross Profit 36.4% 39.3% 34.2% 38.6% R&D 5.9%
5.8% 5.9% 5.8% SG&A 16.3% 15.7% 16.9% 15.9% Income From
Operations 14.3% 17.8% 8.8% 16.9% Income Before Income Taxes 11.2%
14.8% 5.5% 13.7% Net Income 8.8% 11.2% 4.0% 10.2% Income Tax Rate
21.3% 24.0% 27.2% 25.5% % Change vs. Prior Year
----------------------- GAAP Adjusted ------- -------- Net sales
5.6 % 5.6 % Cost of products sold 2.0 % 4.4 % Gross Profit 12.6 %
7.7 % Research and development 6.2 % 5.4 % Acquired in-process
research and development (99.4)% nm Selling, general and
administrative 1.4 % 4.2 % Income From Operations 71.1 % 11.6 %
Interest expense (13.6)% (13.1)% Other expense (income), net
(70.1)% (76.8)% Income Before Income Taxes 117.0 % 13.9 % Income
tax expense 69.8 % 7.0 % Net Income 134.6 % 16.3 % Earnings Per
Common Share: Basic 132.2 % 14.3 % Diluted 134.1 % 15.5 % Weighted
Average Common Shares Outstanding: Basic 1.5 % 1.5 % Diluted 0.7 %
0.7 % A -- Includes intangible assets amortization of $62.8 related
to the Mayne Pharma acquisition; charges of $35.6 related to the
planned closures of the Ashland, OH; Montreal, Canada; North
Chicago, IL; and Morgan Hill, CA facilities as part of Hospira's
facilities optimization initiatives; a gain on the sale of the
Montreal, Canada manufacturing plant ($2.5); and Mayne Pharma
integration and other acquisition- related charges of $8.6. B --
Includes Mayne Pharma integration and other acquisition-related
charges of $1.0 and facilities optimization initiatives of $2.3. C
-- Acquired in-process research and development. D -- Mayne Pharma
integration and other acquisition-related charges. E -- Reflects
the tax effect of the above adjustments. F -- Includes inventory
step-up charge of $53.1 and intangible assets amortization of $47.6
related to the Mayne Pharma acquisition; charges of $37.6 related
to the planned closures of the Donegal, Ireland; Ashland, OH;
Montreal, Canada; and North Chicago, IL facilities as part of
Hospira's facilities optimization initiatives; a reduction of the
obligation associated with the sale of the Salt Lake City, UT
manufacturing plant to ICU Medical ($1.6); Mayne Pharma integration
charges of $7.0; and intangible asset impairment of $7.5 related to
a non-strategic device product. G -- Other acquisition-related
charge: $2.2 of bridge loan fees incurred as a result of the Mayne
Pharma acquisition expensed upon refinancing of loan during the
first quarter of 2007 net of a refund of $1.4 received in the
fourth quarter of 2007. H -- Other acquisition-related charge:
foreign exchange losses related to the Mayne Pharma acquisition. nm
= Percent change is not meaningful. Hospira, Inc. Reconciliation of
Diluted Earnings Per Share (Unaudited) Three Months Ended Years
Ended December 31, December 31, -------------------
-------------------- 2008 2007 2008 2007 ------ ------ ------
------ Diluted Earnings Per Share - GAAP $0.65 $0.47 $1.99 $0.85
Adjustments: Mayne Pharma acquisition related: Acquired in-process
research and development - - - 0.53 Inventory step-up charge - - -
0.23 Integration and other acquisition- related charges 0.02 0.04
0.12 0.21 Intangible assets amortization 0.06 0.06 0.27 0.20
Charges related to facilities optimization initiatives 0.04 0.02
0.15 0.14 Intangible asset impairment related to a non-strategic
device product - 0.03 - 0.03 Acquired in-process research and
development related to product acquisition - 0.01 - 0.01
Integration and other acquisition-related charges 0.01 - 0.01 -
Gain on the sale of the Montreal, Canada manufacturing plant - -
(0.01) - Reduction of obligation associated with the sale of the
Salt Lake City, UT manufacturing plant - - - (0.01) ------ ------
------ ------ Subtotal of Adjustments 0.13 0.16 0.54 1.34 Diluted
Earnings Per Share - Adjusted $0.78 $0.63 $2.53 $2.19 ====== ======
====== ====== Hospira, Inc. Condensed Consolidated Balance Sheets
(Unaudited) (dollars in millions) December 31, December 31, Assets
2008 2007 -------- -------- Current Assets: Cash and cash
equivalents $483.8 $241.1 Trade receivables, less allowances of
$6.7 in 2008 and $14.1 in 2007 583.4 559.0 Inventories 830.5 766.6
Deferred income taxes 172.2 176.7 Prepaid expenses 35.7 23.8 Other
receivables 43.7 73.8 -------- -------- Total Current Assets
2,149.3 1,841.0 -------- -------- Property and equipment, net
1,192.1 1,276.9 Intangible assets, net 404.4 554.0 Goodwill 1,167.4
1,240.9 Deferred income taxes 70.1 79.4 Investments 37.6 23.7 Other
assets 53.2 68.8 -------- -------- Total Assets $5,074.1 $5,084.7
======== ======== Liabilities and Shareholders' Equity Current
Liabilities: Short-term borrowings $338.3 $58.5 Trade accounts
payable 231.5 190.3 Salaries, wages and commissions 144.7 143.6
Deferred income taxes 1.5 8.4 Other accrued liabilities 331.5 393.5
-------- -------- Total Current Liabilities 1,047.5 794.3 --------
-------- Long-term debt 1,834.0 2,184.4 Deferred income taxes 25.2
50.7 Post-retirement obligations and other long-term liabilities
391.0 310.1 Commitments and Contingencies -------- -------- Total
Shareholders' Equity 1,776.4 1,745.2 -------- -------- Total
Liabilities and Shareholders' Equity $5,074.1 $5,084.7 ========
======== Hospira, Inc. Condensed Consolidated Statements of Cash
Flows (Unaudited) (dollars in millions) Years Ended December 31,
------------------------ 2008 2007 -------- -------- Cash Flow From
Operating Activities: Net income $320.9 $136.8 Adjustments to
reconcile net income to net cash from operating activities --
Depreciation 183.2 183.0 Amortization of intangibles 68.7 52.1
Write-off of acquired in-process research and development 0.5 88.0
Step-up value of acquired inventories sold - 53.1 Stock-based
compensation expense 42.0 39.4 Impairment of long-lived assets -
7.5 Net gains on sales of assets (3.0) (5.0) Changes in assets and
liabilities -- Trade receivables (55.4) (47.6) Inventories (117.9)
34.4 Prepaid expenses and other assets 12.9 17.7 Trade accounts
payable 49.5 11.5 Other liabilities 52.9 (40.3) Other, net 29.8
20.5 -------- -------- Net Cash Provided by Operating Activities
584.1 551.1 -------- -------- Cash Flow From Investing Activities:
Capital expenditures (including instruments placed with or leased
to customers) (164.3) (210.5) Acquisitions, net of cash acquired,
including payments for deferred consideration (26.1) (1,980.5)
Purchases of intangibles and other investments (50.8) (5.5)
(Purchases) Sales of marketable securities (24.5) 10.4 Settlements
of foreign currency contracts - (55.7) Proceeds from dispositions
of product rights - 13.8 Proceeds from disposal of facilities 0.8 -
-------- -------- Net Cash Used in Investing Activities (264.9)
(2,228.0) -------- -------- Cash Flow From Financing Activities:
Issuance of long-term debt, net of fees paid - 3,336.2 Repayment of
long-term debt (95.2) (1,825.2) Other borrowings, net 6.3 (6.2)
Excess tax benefit from stock-based compensation arrangements 1.0
2.3 Proceeds from stock options exercised 27.8 73.1 --------
-------- Net Cash (Used in) Provided by Financing Activities (60.1)
1,580.2 -------- -------- Effect of exchange rate changes on cash
and cash equivalents (16.4) 15.8 -------- -------- Net change in
cash and cash equivalents 242.7 (80.9) Cash and cash equivalents at
beginning of year 241.1 322.0 -------- -------- Cash and cash
equivalents at end of year $483.8 $241.1 ======== ========
Supplemental Cash Flow Information: Cash paid during the year --
Interest $120.8 $127.4 Income taxes, net of refunds $14.9 $72.4
Hospira, Inc. Net Sales by Product Line (Unaudited) (dollars in
millions) Three Months Ended December 31,
---------------------------------------- % Change % Change at
Actual at Constant 2008 2007 Rates Rates -------- -------- -------
------- Americas -- Pharmaceuticals Specialty Injectables $347.2
$349.7 (0.7)% 1.3 % Other Pharma 147.6 155.6 (5.1)% (2.4)% --------
-------- 494.8 505.3 (2.1)% 0.1 % Devices Medication Management
Systems 140.6 129.1 8.9 % 12.4 % Other Devices 85.8 94.1 (8.8)%
(6.6)% -------- -------- 226.4 223.2 1.4 % 4.3 % Total Americas
721.2 728.5 (1.0)% 1.4 % Europe, Middle East & Africa --
Pharmaceuticals Specialty Injectables 63.2 71.1 (11.1)% 0.3 % Other
Pharma 31.9 51.0 (37.5)% (25.8)% -------- -------- 95.1 122.1
(22.1)% (10.6)% Devices Medication Management Systems 16.7 16.6 0.6
% 11.6 % Other Devices 16.0 16.9 (5.3)% 5.6 % -------- --------
32.7 33.5 (2.4)% 8.5 % Total Europe, Middle East & Africa 127.8
155.6 (17.9)% (6.5)% Asia Pacific -- Pharmaceuticals Specialty
Injectables 50.1 47.3 5.9 % 27.7 % Other Pharma 3.1 3.3 (6.1)% 21.2
% -------- -------- 53.2 50.6 5.1 % 27.2 % Devices Medication
Management Systems 4.4 4.4 0.0 % 11.9 % Other Devices 7.1 7.0 1.4 %
5.7 % -------- -------- 11.5 11.4 0.9 % 8.1 % Total Asia Pacific
64.7 62.0 4.4 % 23.8 % -------- -------- Net Sales $913.7 $946.1
(3.4)% 1.6 % ======== ======== Years Ended December 31,
---------------------------------------- % Change % Change at
Actual at Constant 2008 2007 Rates Rates -------- -------- -------
------- Americas -- Pharmaceuticals Specialty Injectables $1,328.9
$1,240.9 7.1 % 7.1 % Other Pharma 522.0 549.2 (5.0)% (4.7)%
-------- -------- 1,850.9 1,790.1 3.4 % 3.5 % Devices Medication
Management Systems 558.9 501.3 11.5 % 11.4 % Other Devices 368.5
367.5 0.3 % 0.1 % -------- -------- 927.4 868.8 6.7 % 6.6 % Total
Americas 2,778.3 2,658.9 4.5 % 4.5 % Europe, Middle East &
Africa -- Pharmaceuticals Specialty Injectables 287.4 255.4 12.5 %
8.0 % Other Pharma 152.1 162.3 (6.3)% (8.1)% -------- --------
439.5 417.7 5.2 % 1.8 % Devices Medication Management Systems 75.9
66.4 14.3 % 7.6 % Other Devices 68.4 68.0 0.6 % (4.6)% --------
-------- 144.3 134.4 7.4 % 1.4 % Total Europe, Middle East &
Africa 583.8 552.1 5.7 % 1.6 % Asia Pacific -- Pharmaceuticals
Specialty Injectables 205.4 168.9 21.6 % 19.6 % Other Pharma 15.2
14.1 7.8 % 4.8 % -------- -------- 220.6 183.0 20.5 % 18.4 %
Devices Medication Management Systems 19.9 16.7 19.2 % 15.5 % Other
Devices 26.9 25.5 5.5 % (0.7)% -------- -------- 46.8 42.2 10.9 %
5.7 % Total Asia Pacific 267.4 225.2 18.7 % 16.1 % --------
-------- Net Sales $3,629.5 $3,436.2 5.6 % 4.8 % ======== ========
Notes: Specialty Injectables include generic injectables and
proprietary specialty injectables. Other Pharmaceuticals include
large volume IV solutions, nutritionals and contract manufacturing
services (including former "Sales to Abbott"). Medication
Management Systems include infusion pumps, related software,
services and administration sets. Other Devices include gravity
administration sets, critical care products, and other device
products. Net sales for the years ended December 31, 2008 and 2007,
include twelve and eleven months, respectively, of Mayne Pharma net
sales. Hospira, Inc. Segment Information (Unaudited) (dollars in
millions) Three Months Ended December 31,
---------------------------------------------------------- Net
Sales Income from Operations ----------------- ------------------ %
% 2008 2007 Change 2008 2007 Change ------ ------ ------ ------
------ ------ Americas $721.2 $728.5 (1.0)% $172.0 A $142.4 A 20.8
% Europe, Middle East & Africa 127.8 155.6 (17.9)% 2.1 B (0.4)B
625.0 % Asia Pacific 64.7 62.0 4.4 % 9.4 C 4.9 C 91.8 % ------
------ ------ ------ Total reportable segments $913.7 $946.1 (3.4)%
183.5 146.9 24.9 % ====== ====== Corporate functions (19.0)D
(25.1)D (24.3)% Stock-based compensation (8.8) (7.8) 12.8 % ------
------ Income from operations 155.7 114.0 36.6 % Interest expense
and other income, net (29.6)E (24.3)E 21.8 % ------ ------ Income
before income taxes $126.1 $89.7 40.6 % ====== ====== Included in
the reported Income before income taxes above, are the following
charges: A -- Americas Mayne Pharma acquisition related: Acquired
in-process research and development $ - $ - Inventories step-up
charge - - Integration and other acquisition- related charges 1.5
1.8 Intangible assets amortization 4.2 2.0 Charges related to
facilities optimization initiatives 9.5 3.5 Intangible asset
impairment related to a non-strategic device product - 7.5
Integration and other acquisition- related charges 0.1 - Acquired
in-process research and development - - Gain on the sale of the
Montreal, Canada manufacturing plant - - Reduction of obligation
associated with the sale of the Salt Lake City, UT manufacturing
plant - - ------ ------ Total Americas 15.3 14.8 B -- Europe,
Middle East & Africa Mayne Pharma acquisition related: Acquired
in-process research and development - - Inventories step-up charge
- - Integration and other acquisition- related charges 0.5 4.3
Intangible assets amortization 8.1 5.8 Charges related to
facilities optimization initiatives - 0.6 Acquired in-process
research and development - 3.2 ------ ------ Total Europe, Middle
East & Africa 8.6 13.9 C -- Asia Pacific Mayne Pharma
acquisition related: Inventories step-up charge - - Integration and
other acquisition- related charges 1.6 1.7 Intangible assets
amortization 3.7 4.8 Integration and other acquisition- related
charges 0.2 - ------ ------ Total Asia Pacific 5.5 6.5 D --
Corporate functions Integration and other acquisition- related
charges 3.1 4.4 ------ ------ Total Corporate functions 3.1 4.4 E
-- Interest expense and other income, net Integration and other
acquisition- related charges, net of refund - (1.4) ------ ------
Total Interest expense and other income, net - (1.4) ------ ------
Total $32.5 $38.2 ====== ====== Hospira, Inc. Segment Information
(Unaudited) (dollars in millions) Years Ended December 31,
---------------------------------------------------------- Net
Sales Income from Operations ------------------- ------------------
% % 2008 2007 Change 2008 2007 Change -------- -------- ------
------ ------ ------ Americas $2,778.3 $2,658.9 4.5 % $598.0 A
$445.3 A 34.3 % Europe, Middle East & Africa 583.8 552.1 5.7 %
12.8 B (16.6)B 177.1 % Asia Pacific 267.4 225.2 18.7 % 23.0 C
(4.2)C 647.6 % -------- -------- ------ ------ Total reportable
segments $3,629.5 $3,436.2 5.6 % 633.8 424.5 49.3 % ========
======== Corporate functions (74.0)D (82.5)D (10.3)% Stock-based
compensation (42.0) (39.4) 6.6 % ------ ------ Income from
operations 517.8 302.6 71.1 % Interest expense and other income,
net (110.3)E (114.8)E (3.9)% ------ ------ Income before income
taxes $407.5 $187.8 117.0 % ====== ====== Included in the reported
Income before income taxes above, are the following charges: A --
Americas Mayne Pharma acquisition related: Acquired in-process
research and development $ - $66.2 Inventories step-up charge -
10.0 Integration and other acquisition- related charges 3.6 14.8
Intangible assets amortization 19.2 9.4 Charges related to
facilities optimization initiatives 37.9 35.7 Intangible asset
impairment related to a non-strategic device product - 7.5
Integration and other acquisition- related charges 0.1 - Acquired
in-process research and development 0.5 - Gain on the sale of the
Montreal, Canada manufacturing plant (2.5) - Reduction of
obligation associated with the sale of the Salt Lake City, UT
manufacturing plant - (1.6) ------ ------ Total Americas 58.8 142.0
B -- Europe, Middle East & Africa Mayne Pharma acquisition
related: Acquired in-process research and development - 18.6
Inventories step-up charge - 18.0 Integration and other
acquisition- related charges 10.6 6.4 Intangible assets
amortization 25.8 21.5 Charges related to facilities optimization
initiatives - 1.9 Acquired in-process research and development -
3.2 ------ ------ Total Europe, Middle East & Africa 36.4 69.6
C -- Asia Pacific Mayne Pharma acquisition related: Inventories
step-up charge - 25.1 Integration and other acquisition- related
charges 7.1 3.6 Intangible assets amortization 17.8 16.7
Integration and other acquisition- related charges 1.4 0.6 ------
------ Total Asia Pacific 26.3 46.0 D -- Corporate functions
Integration and other acquisition- related charges 7.8 19.4 ------
------ Total Corporate functions 7.8 19.4 E -- Interest expense and
other income, net Integration and other acquisition- related
charges, net of refund - 6.5 ------ ------ Total Interest expense
and other income, net - 6.5 ------ ------ Total $129.3 $283.5
====== ====== http://www.newscom.com/cgi-bin/prnh/20040503/HSPLOGO
http://photoarchive.ap.org/ DATASOURCE: Hospira, Inc. CONTACT:
Media, Stacey Eisen, +1-224-212-2276, or Tareta Adams,
+1-224-212-2535, or Financial Community, Karen King,
+1-224-212-2711, all of Hospira, Inc. Web site:
http://www.hospira.com/
Copyright
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024